Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

Status Unknown status

Clinical Trial Summary

This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the study medication as well as across multiple attacks of cluster headache. This study seeks to determine the safety and efficacy of the commercially available 4mg StatDose formulation of sumatriptan as an acute treatment of cluster headache. Patients are allowed to use repeated dose of the study medication for a given headache if they have had a partial response to the first dose. They may treat up to 3 attacks of cluster headache with the study medication. Safety assessment will be through adverse event reporting and physical examination. Patients with both episodic cluster headache as well as chronic cluster headache will be studied. Patients must either not have started preventive treatment for cluster headache or be on a stable dose of preventive medication.

Clinical Trial Description

This is an open label trial of sumatriptan 4 mg using the StatDose injector system for the treatment of acute attacks of cluster headache.

Patient entering the trial must either be in the first 3 weeks of an episodic cluster headache cycle or have chronic cluster headache. Patients with episodic cluster headache may have not begun taking preventive medications at the time of study or must be on a stable regimen of preventive medications. Patients with chronic cluster headache must be on a stable regimen of preventive medications.

Patients must be in good health with no contraindications to the use of sumatriptan such as either having or having increased risk factors for CAD or CVD. They may not take during the time of the study preventive medications that are 5HT1B/1D agonists. Episodic use of triptans, ergotamine, or dihydroergotamine is permitted provided they are not used within 24 hours of use of the study medication.

Patients will be required to treat 3 acute attacks of cluster headache with the study medication or to use more than 1 dose of study medication to fully treat an individual attack of cluster headache with a maximum of 3 doses of the study medication within a 24 hour time frame.

Efficacy of the study medication will be determined from diary data collected. Safety data will be determined by adverse events reported by the patient. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00399243
Study type	Interventional
Source	Diamond Headache Clinic
Contact	Fred G Freitag, DO
Phone	773 388 6390
Email	research@diamondheadache.com
Status	Unknown status
Phase	Phase 4
Start date	November 2006
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02462395` - Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache	Phase 2/Phase 3
Completed	`NCT05064397` - A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)	Phase 3
Recruiting	`NCT01701245` - Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care	Phase 2
Completed	`NCT01151631` - Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache	Phase 3
Recruiting	`NCT06124534` - Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH	N/A
Recruiting	`NCT05868044` - REsponse to Combined SONS and ONS in Chronic Cluster headachE	N/A
Completed	`NCT01616511` - Pathway CH-1 Long-Term Follow-Up	N/A
Completed	`NCT01359631` - Cephalic Vascular Recording Upon SPG Stimulation	N/A
Completed	`NCT02438826` - A Study of Galcanezumab in Participants With Chronic Cluster Headache	Phase 3
Completed	`NCT02510729` - SPG Neurostimulation in Cluster Patients	N/A
Active, not recruiting	`NCT02168764` - Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache	N/A
Completed	`NCT02797951` - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache	Phase 3
Not yet recruiting	`NCT05477459` - LSD to Improve Cluster Headache Impact Trial	Phase 2
Completed	`NCT03244735` - Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series	N/A
Terminated	`NCT02964338` - A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)	Phase 3
Completed	`NCT01255813` - Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache	N/A
Active, not recruiting	`NCT05023460` - Treatment of Chronic Cluster Headache With TENS and ONS	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.